FDA Approves Vizz Eye Drops to Enhance Near Vision in Adults

The U.S. Food and Drug Administration (FDA) has officially approved Vizz 1.44% (aceclidine ophthalmic solution), a groundbreaking treatment for presbyopia in adults. This marks the first and only eye drop based on aceclidine designed specifically to improve near vision in the adult population. The medication functions by contracting the iris sphincter muscle, producing a pinhole effect that results in a pupil size of less than 2 mm. This mechanism increases depth of focus, significantly enhancing near vision without inducing a myopic shift.

The approval was supported by comprehensive data from three phase 3 clinical trials—CLARITY 1, CLARITY 2, and CLARITY 3—covering safety and efficacy over time. In these studies, involving 466 participants dosed once daily for 42 days and 217 participants observed for six months, Vizz demonstrated rapid improvement in near vision within 30 minutes of application, with effects lasting up to 10 hours. The trials reported no serious adverse events related to the treatment, and most side effects such as mild eye irritation, temporary dim vision, and headaches were transient and self-resolving.

Lead investigator Marc Bloomenstein, O.D., from the Schwartz Laser Eye Care Center in Scottsdale, Arizona, expressed enthusiasm about the treatment's potential impact. He highlighted that Vizz could revolutionize current options for managing presbyopia, offering a highly effective, patient-friendly alternative. This new approach is anticipated to become a standard in presbyopia treatment, providing relief for millions experiencing age-related difficulty in near vision.

The approval was granted to LENZ Therapeutics, reinforcing the company's commitment to innovative ophthalmic solutions. For more details, further information can be found at source.